INDBInternet News Database 2.5 Updated 1 min ago · 315 sources Show or hide images Light or dark

Q&A: Why the Jury Is Still Out on Durvalumab for NMIBC

Save Like Comments Compare coverage

Summary

Despite a recent FDA approval, urologic oncologists are waiting for more data before embracing durvalumab add-on for patients with high-risk non-muscle invasive bladder cancer.

Description from Medscape.

Who is covering this

  1. Medscape Center Factuality: Mostly factual US
    Q&A: Why the Jury Is Still Out on Durvalumab for NMIBC

    Despite a recent FDA approval, urologic oncologists are waiting for more data before embracing durvalumab add-on for patients with high-risk non-muscle invasive bladder cancer.

Comments

Comments need JavaScript.